OCX Oncocyte

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights.

Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” section of the Company’s website at  A replay of the webcast will be available on the Company’s website shortly after the conclusion of the call. 

CONFERENCE CALL DETAILS:

Participant Toll-Free Dial-In Number: (800) 715-9871

Participant Toll Dial-In Number: +1 (646) 307-1963

Conference ID: 4153469

WEBCAST DETAILS:

About Oncocyte

Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit .

For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - VitaGraft Liver™ - 

GraftAssure™ - DetermaIO™ - DetermaCNI™ - 

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:

Jeff Ramson

PCG Advisory

(646) 863-6893



EN
06/11/2024

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Trans...

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third ...

November 12, 2024 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights. ...

November 6, 2024 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Announces Participation in the LD Micro Main Event XVII Confe...

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory () or request a meeting via the LD Micro Conference platform. Event: LD Micro Main Event...

October 16, 2024 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezol...

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed of positive data related to its proprietary gene expression test, DetermaIO™. The...

October 8, 2024 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Signs Leading Transplant Centers in US and Germany

Oncocyte Signs Leading Transplant Centers in US and Germany GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both have entered into agreements with the...

October 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch